Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
CH0461929603
Tue, 08.02.2022
Xlife Sciences AG
Media Release
Zurich, February 8, 2022, 8 pm CET
Xlife Sciences publishes prospectus for listing on SIX Swiss Exchange
Xlife Sciences AG (XLS DE) today has published the prospectus for its intended listing on the "Sparks" segment of SIX Swiss Exchange. The listing and commencement of trading is scheduled for February 11, 2022 (from 3 pm CET*), as [ … ]
Tue, 01.02.2022
Xlife Sciences AG
Media Release
Zurich, February 1, 2022, 8 pm CET
Xlife Sciences: Listing and first trading day on the "Sparks" segment of SIX Swiss Exchange expected for February 11, 2022
Xlife Sciences AG (XLS DE) intends to list and commence trading of its shares on the SME equity segment "Sparks" of SIX Swiss Exchange on February 11, 2022, under the stock exch [ … ]
Wed, 26.01.2022
Xlife Sciences AG
Media Release
Zurich, January 26, 2022, 7 am CET
Xlife Sciences raises CHF 5.0 million through capital increase
Xlife Sciences AG (XLS DE) has decided and executed a capital increase on January 25, 2022. It consists of the issuance of 108'495 new shares at a price of CHF 46.20 each in a private placement. In addition, 31'360 new shares were issued [ … ]
Mon, 10.01.2022
Xlife Sciences AG
Media Release
Xlife Sciences plans listing on the "Sparks" segment of SIX Swiss Exchange
- Listing on the new "Sparks" segment of SIX Swiss Exchange for small and medium-sized companies is planned for Q1 2022, subject to market environment
- Xlife Sciences AG is a Swiss company focused on the value development and commercialization of promising [ … ]
Wed, 01.12.2021
Xlife Sciences AG
DGAP-Media / 01.12.2021 / 08:00
DGAP Press release
December 1, 2021 08.00 am CET
Media release
Xlife Sciences appoints new Chief Financial Officer
Xlife Sciences (XLS DE) announced that Carl von Halem has been appointed as the Company's new Chief Financial Officer, effective as of today, 1 December 2021. Beat Kläui, who has been interim [ … ]
Thu, 18.11.2021
Xlife Sciences AG
DGAP Ad-hoc-Service
November 18, 8 pm CET
Media release
Xlife Sciences (XLS DE) explores listing on SIX Swiss Exchange
Xlife Sciences, a Swiss company developing new technologies and treatments in the life sciences sector and currently admitted to trading on the Munich Stock Exchange, today announced that it is exploring the possibility of a li [ … ]
Tue, 26.10.2021
Xlife Sciences AG
MEDIA INFORMATIONXlife Sciences AG (XLS DE): Partnership with Vision 2030
Xlife Sciences AG is elected as Innovation Partner for Saudi Arabia Xlife Sciences AG has signed a strategic partnership with the development organization Peace City World as part of the Vision 2030 future program. Peace City World is the official developer of four Smart Cit [ … ]
Thu, 07.10.2021
Xlife Sciences AG
DGAP-Media / 07.10.2021 / 09:05
MEDIA INFORMATION
Xlife Sciences AG (XLS DE): Successful license deal with Vitese Trading GmbHInflamed pharma GmbH signs license agreement with Vitesse Trading GmbH
The Xlife-project company inflamed pharma GmbH has concluded an exclusive license agreement with the Austrian Vitesse Trading GmbH for the sale [ … ]
Tue, 22.06.2021
Xlife Sciences AG
DGAP-Media / 22.06.2021 / 06:50
PRESS RELEASE
Zurich,Xlife Sciences AG (XLS DE): Collaboration with the University of Marburg
Inventum Genetics GmbH and Universität Marburg agree on a collaborationThe project company of Xlife Sciences AG Inventum Genetics GmbH has signed a collaboration agreement with the Philipps-University of Marburg. In [ … ]
Wed, 16.06.2021
Xlife Sciences AG
DGAP-Media / 16.06.2021 / 06:30
PRESS RELEASE
Zurich, Kleinostheim,Xlife Sciences AG (XLS DE): curasan AG and Xlife Sciences AG cooperate in the field of regenerative medicine
curasan AG, a leading global provider of biomaterials for bone and tissue regeneration in dental and orthopedic surgery, and Xlife Sciences AG have initiated a collabo [ … ]